Synthesis and biological evaluation of 1,2,4-triazolo[2,3-a]pyrrole derivatives as alpha-4 (α4) integrin antagonists

Letters in Drug Design and Discovery

Volumn 2, Issue 8, 2005, Pages 601-605

  Lawson, Edward C ^a   Kinney, William A ^a   Santulli, Rosemary J ^a   Fisher, Carol M ^a   Damiano, Bruce P ^a   Maryanoff, Bruce E ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; ALPHA4 INTEGRIN; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; PROTEIN INHIBITOR; PYRROLE DERIVATIVE; TR 14035; TR 14531; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

EID: 29044440726     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018005774717280     Document Type: Article

References (47)

1. Humphries, M. J. Biochem. Soc. Trans. 2000, 28, 311.
2. Osborn, L.; Hession, C.; Tizard, R.; Vassallo, C.; Luhowskyj, S.; Chi-Rosso, G.; Lobb, R. Cell 1989, 59, 1203.
3. Wayner, E. A.; Garcia-Pardo, A.; Humphries, M. J.; McDonald, J. A.; Carter, W. G. J. Cell Biol. 1989, 109, 1321.
4. For review articles on VLA-4 antagonists, see: (a) Hagmann, W. K. Curr. Top. Med. Chem. 2004, 4, 1461
5. (b) Yang, G. X.; Hagmann, W. K. Med. Res. Rev. 2003, 23, 369
6. (c) Tilley, J. W.; Chen, L.; Sidduri, A.; Fotouhi, N. Curr. Top. Med. Chem. 2004, 4, 1509
7. (d) Tilley, J. W. Exp. Opin. Ther. Pat. 2002, 12, 991
8. (e) Lin, K.-C.; Castro, A. C. Curr. Opin. Chem. Biol. 1998, 2, 453
9. (f) Huryn, D. M.; Konradi, A.; Kennedy, J. D. Curr. Top. Med. Chem. 2004, 4, 1473
10. (g) Singh, J.; Adams, S.; Carter, M. B.; Cuervo, H.; Lee, W.-C.; Lobb, R. R.; Pepinsky, R. B.; Petter, R.; Scott, D. Curr. Top. Med. Chem. 2004, 4, 1497
11. (h) Adams, S. P.; Lobb, R. R. Annu. Rep. Med. Chem. 1999, 34, 179
12. (i) Holland, G. W.; Biediger, R. J.; Vanderslice, P. Annu. Rep. Med. Chem. 2002, 37, 65.
13. Kubes, P.; Niu, X.-F.; Smith, C. W.; Kehrli, M. E., Jr.; Reinhardt, P. H.; Woodman, R. C. FASEB J. 1995, 9, 1103.
14. Chuluyan, H. E.; Issekutz A. C. Springer Semin, Immunopathol. 1995. 16, 391
15. Chem.Abstr. 123:53627.
16. Sampaio, S. O.; Li, X.; Takeuchi, M.; Mei, C.; Francke, U.; Butcher, E. C.; Briskin, M. J. J. Immunol. 1995, 155, 2477;
17. Shyjan, A. M.; Bertagnolli, M.; Kenney, C. J.; Briskin, M. J. J. Immunol. 1996, 156, 2851.
18. 7 antagonists, see: (a) Jackson, D. Y. Curr. Pharm. Des. 2002, 8, 1229
19. (b) Dubree, N. J. P.; Artis, D. R.; Castanedo, G.; Marsters, J.; Sutherlin, D.; Caris, L.; Clark, K.; Keating, S. M.; Beresini, M. H.; Chiu, H.; Fong, S.; Lowman, H. B.; Skelton, N. J.; Jackson, D. Y. J. Med. Chem. 2002, 45, 3451.
20. Shroff, H. N.; Schwender, C. F.; Baxter, A. D.; Brookfield, F.; Payne, L. J.; Cochran, N. A.; Gallant, D. L.; Briskin, M. J. Bioorg. Med. Chem. Lett. 1998, 8, 1601.
21. Yoshikawa, H.; Sakihama, T.; Nakajima, Y.; Tasaka, K. J. Immunol. 1996, 156, 1832.
22. Yusuf-Makagiansar, H.; Anderson, M. E.; Yakovleva, T. V.; Murray, J. S.; Siahaan, T. J. Med. Res. Rev. 2002, 22, 146.
23. (a) Miller, D. H.; Khan, O. A.; Sheremata, W. A.; Blumhardt, L. D.; Rice, G. P. A.; Libonati, M.; Willmer-Hulme, A. J.; Datton, C. M.; Miszkiel, K. A.; O'Connor, P. W. International Natalizumab Multiple Sclerosis Trial Group. New Engl. J. Med. 2003, 348, 15.
24. O'Connor, P. W.; Goodman, A.; Willmer-Hulme, A. J.; Libonati, M. A.; Metz, L.; Murray, R. S.; Sheremata, W. A.; Vollmer, T. L.; Stone, L. A. Neurology 2004, 62, 2038
25. (b) Ghosh, S.; Goldin, E.; Gordon, F. H.; Malchow, H. A.; Rask-Madsen, J.; Rutgeerts, P.; Vyhnakek, P.; Zadorova, Z.; Palmer, T.; Donoghue, S. Natalizumab Pan-European Study Group. New Engl. J. Med. 2003, 348, 24.
26. (a) Dyatkin, A. B.; Hoekstra, W. J.; Kinney, W. A.; Kontoyianni, M.; Santulli, R. J.; Kimball, E. S.; Fisher, M. C.; Prouty, S. M.; Abraham, W. M.; Andrade-Gordon, P.; Hlasta, D. J.; He, W.; Hornby, P. J.; Damiano, B. P.; B. E. Maryanoff, Bioorg. Med. Chem. Lett., 14, 591 (2004)
27. (b) Dyatkin, A. B.; Gong, Y.; Miskowski, T. A.; Kimball, E. S.; Prouty, S. M.; Fisher, M. C.; Santulli, R. J.; Schneider, C. R.; Wallace, N. H.; Hornby, P. J.; Diamond, C.; Kinney, W. A.; Maryanoff, B. E.; Damiano, B. P.; He, W. Bioorg. Med. Chem. 2005, 13, in press
28. (c) Dyatkin, A. B.; Maryanoff, B. E.; Hoekstra, W. J.; He, W.; Kinney, W. A. PCT Intl. Appl. 2002, WO 2002002556 [Chem. Abstr. 136:86057]
29. (d) Miskowski, T. A.; Gong, Y.; Dyatkin, A. B.; He, W. PCT Intl. Appl. 2005, WO 2005042529 [Chem. Abstr. 142:464018].
30. (a) Lawson, E. C.; Hoekstra, W. J.; Addo, M. F.; Andrade-Gordon, P.; Damiano, B. P.; Kauffman, J. A.; Mitchell, J. A.; Maryanoff, B. E. Bioorg. Med. Chem. Lett. 2001, 11, 2619
31. (b) Hoekstra, W. J.; Lawson, E. C.; Maryanoff, B. E. PCT Intl. Appl. 2000, WO 2000006570 [Chem. Abstr. 132:151823].
32. Chen, L.; Tilley, J. W.; Guthrie, R. W.; Mennona, F.; Huang, T.-N.; Kaplan, G.; Trilles, R.; G.; Miklowski, D.; Huby, N.; Schwinge, V.; Wolitzky, B.; Rowan, K. Bioorg. Med. Chem. Lett. 2000, 10, 729.
33. Archibald, S. C.; Head, J. C.; Gozzard, N.; Howat, D. W.; Parton, T. A. H.; Porter, J. R.; Robynson, M. K.; Shock, A.; Warellow, G. J.; Abraham, W. M. Bioorg. Med. Chem. Lett. 2000, 10, 997.
34. Lawson, E. C.; Maryanoff, B. E.; Hoekstra, W. J. Tetrahedron Lett. 2000, 41, 4533.
35. (a) Rothchild, R. Enantiomer 2000, 5, 457
36. (b) Pirkle, W. H.; Adams, P. E. J. Org. Chem. 1979, 44, 169
37. Pirkle, W. H.; Adams, P. E. J. Org. Chem. 1980, 45, 4117.
38. Prepared by addition of dimethylcarbamoyl chloride to a stirred mixture of from L-tyrosine methyl ester and NaH in THF/DMSO at -10 to 0 °C.
39. Prepared from Boc-4-nitrophenylalanine following literature reference: Sidduri, A.; Tilley, J. W.; Lou, J. P.; Chen, L.; Kaplan, G.; Mennona, F.; Campbell, R.; Guthrie, R.; Huang, T. N.; Rowan, K.; Schwinge, V.; Renzetti, L. M. Bioorg. Med. Chem. Lett. 2002, 12, 2479.
40. (a) Weetell, M.; Hugo, R.; Friedman, C.; Maida, S.; West, S.; Wattanasin, S.; Bouhel, R.; Weitz-Schmidt, G.; Lake, P. Anal. Biochem. 2001, 293, 277
41. (b) Vanderslice, P.; Ren, K.; Revelle, J. K.; Kim, D. C.; Scott, D.; Bjercke, R. J.; Yeh, E. T. H.; Beck, P. J.; Kogan, T. P. J. Immunol. 1997, 158, 1710
42. Our assay conditions were developed on the basis of the methods described in ref 21a and 21b.
43. Sircar, I.; Gudmundsson, K. S.; Martin, R.; Liang, J.; Nomura, S.; Jayakumar, H.; Teegarden, B. R.; Nowlin, D. M.; Cardarelli, P. M.; Mah, J. R.; Connell, S.; Griffith, R. C.; Lazarides, E. Bioorg. Med. Chem. 2002, 10, 2051.
44. (a) Furth, P. S.; Chiang, S.-L.; Sircar, I.; Griffith, R.; Nowlin, D.; Gorscan, F. S.; Mah, J.; Lazarides, E. Book of Abstracts, 218th ACS National Meeting, New Orleans, Aug. 22-26, 1999, MEDI-061
45. Chem. Abstr. 130:617432
46. (b) Sircar, I.; Gudmundsson, K. S.; Martin, R. PCT Intl. Appl. 1999, WO 9936393 [Chem. Abstr. 131:116517].
47. 4 integrin antagonists: Gong, Y.; Barbay, J. K.; Kimball, E. S.; Fisher, M. C.; Santulli, R. J.; Dyatkin, A. B.; Miskowski, T. A.; Schneider, C. R.; Wallace, N. H.; Prouty, S. M.; Hornby, P. J.; Ballentine, S. A.; Hageman, W. E.; Masucci, J. A.; Maryanoff, B. E.; Damiano, B. P.; Andrade-Gordon, P.; Hlasta, D. J.; He, W., manuscript to be submitted.